logo
  

Pan American Silver Reports Addl Changes To Stock Option,compensation Share Plan

Pan American Silver Corp. (PAAS,PAA.TO) announced additional minor changes to its Stock Option and Compensation Share Plan in order to more closely align the Plan with Institutional Shareholder Services requirements.

In its information circular dated April 7, 2015 the Company disclosed a number of proposed changes to the Plan to be presented to shareholders at the Company's Annual General and Special Meeting to be convened on May 11, 2015.

The Company intends to supplement the proposed amendments to the Plan with the following: the $100,000 limit on the annual equity award for non-employee directors will no longer include an exception for the Chairman of the Board; and the provisions addressing amendments to the Plan will be modified such that the following will require shareholder approval:any amendment to definitions in the Plan; any extension of the term of an option beyond the original expiry date; in addition to reducing the exercise price of an option requiring shareholder approval, as currently set-out in the Plan, any cancellation and reissuance of an option or other entitlement; any amendment which would permit options to be assignable or transferrable, other than for normal estate planning or settlement purposes; any increase to the Annual Equity Limit; and any amendment to the shareholder approval provisions that would increase the ability of the board of directors of the Company to amend the Plan without shareholder approval.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT